The full promise of cell-based immunotherapies depends on technology to engineer and correct targeted genome sequences in primary human immune cells. CRISPR-Cas9 genome editing components can be electroporated into primary cells for gene knock-out. To date, codelivery of oligodeoxynucleotide homology-directed repair (HDR) templates has enabled the replacement of short stretches of nucleotides; however efficient delivery of longer HDR templates has required viral-encoded templates, limiting adaptability and therapeutic applications. Here, we describe methods for non-viral T cell genome targeting with Cas9 RNPs and long (>1 kilobase) non-viral HDR templates. Targeting was efficient across multiple blood donors and genomic loci, cell viability was high, and the procedure could be multiplexed for biallelic or multi-gene targeting. Long single-stranded (ss)DNA HDR templates limited observed off-target integrations using either Cas9 or a Cas9 "nickase." We were able to identify the causal mutations in IL2RA (interleukin-2 receptor alpha; CD25) in multiple siblings with monogenic autoimmunity and correct the mutations in their affected primary T cells. Non-viral genome targeting will allow rapid and flexible experimental manipulation of primary human immune cells and therapeutic engineering of patient cells.
Abstract:
The full promise of cell-based immunotherapies depends on technology to engineer and correct targeted genome sequences in primary human immune cells. CRISPR-Cas9 genome editing components can be electroporated into primary cells for gene knock-out. To date, codelivery of oligodeoxynucleotide homology-directed repair (HDR) templates has enabled the replacement of short stretches of nucleotides; however efficient delivery of longer HDR templates has required viral-encoded templates, limiting adaptability and therapeutic applications. Here, we describe methods for non-viral T cell genome targeting with Cas9 RNPs and long (>1 kilobase) non-viral HDR templates. Targeting was efficient across multiple blood donors and genomic loci, cell viability was high, and the procedure could be multiplexed for biallelic or multi-gene targeting. Long single-stranded (ss)DNA HDR templates limited observed off-target integrations using either Cas9 or a Cas9 "nickase." We were able to identify the causal mutations in IL2RA (interleukin-2 receptor alpha; CD25) in multiple siblings with monogenic autoimmunity and correct the mutations in their affected primary T cells. Non-viral genome targeting will allow rapid and flexible experimental manipulation of primary human immune cells and therapeutic engineering of patient cells.
One Sentence Summary:
We developed non-viral methods to engineer long genome sequences in human T cells, enabling functional studies and correction of autoimmune mutations in patient cells.
Main Text:
Human T cells can be purified from blood, engineered ex vivo, and then returned to circulation through autologous transplantation. Engineered T cells are being developed to treat cancer and infectious diseases (1, 2) . These cell-based treatments depend on the ability to genetically reprogram T cells, for example to enhance their ability to recognize and attack specific antigens (3) . Cell-based therapies involving modified regulatory T cells (Tregs) designed to suppress inflammation are being developed for autoimmune diseases and organ transplantation (4) . Rapid advances in genome engineering have raised hopes that conventional T cells and Tregs can be reprogrammed using precise genome targeting.
A variety of approaches have been used to modify the genomes of primary human T cells. Long DNA sequences (multiple kilobases) can be inserted using lentiviral vectors, but the integration sites are non-targeted (5) . Lentiviruses have been the primary means to introduce gene constructs such as chimeric antigen receptors (CARs) (6) . To knock out specific endogenous genes, sequence specific nucleases such as Cas9, TALEN or zinc-finger nuclease (ZFN) can be electroporated into T cells (7, 8) , generating double-stranded breaks that result in a non-random spectrum of insertions and deletion mutations through non-homologous end-joining (NHEJ) (9) . Co-delivery of small (<200 bp) chemically synthesized ssDNA oligos (ssODNs) that have homology to the sequences flanking a specific nuclease cleavage site has been used to modify short DNA sequences via homology directed repair (7) .
The targeted integration of much longer DNA sequences would enable more diverse applications. This has recently been achieved by electroporation of a sequence-specific nuclease followed by infection with an integrase-deficient adeno-associated vector (AAV) containing an HDR template (10, 11) . This electroporation and infection approach has enabled novel therapeutic T cell engineering strategies (12) but causes off-target integrations, necessitates a potentially undesirable viral infection, and is limited in throughput due to challenges in viral production.
We systematically tested cell culture conditions, concentrations of Cas9 RNPs and HDR templates and electroporation parameters to develop an optimized method for high-efficiency non-viral genome targeting. We identified conditions where high concentrations of Cas9 RNPs and long DNA templates (>1 Kb) could be co-delivered into multiple loci in primary human T cells with limited effects on cell viability.
Non-viral targeting could be used to correct a pathogenic mutation that causes Treg dysfunction and monogenic autoimmune disease. We describe a family where two children have developed early onset autoimmune disease and a third has autoantibodies suggesting a very high risk of type 1 diabetes (T1D) and identified the causal loss-of-function mutations in IL2RA through exome sequencing. IL2RA is critical for regulatory T cell function and immune homeostasis. With our optimized non-viral CRISPR genome targeting, we achieved efficient mutation correction, which restored cell surface expression of IL2RA along with functional downstream signaling. Non-viral genome targeting in primary human immune cells will enable functional studies and correction of mutations in cells from patients. Cell therapies coupled with improved gene targeting (non-viral templates, high efficiency and specificity, and long targeting constructs) hold enormous promise for treatment of autoimmune diseases as well as immune deficiencies, infectious diseases, organ transplantation and cancer immunotherapy.
Development of non-viral human T cell genome targeting
A major limitation for genome targeting in human T cells has been that DNA delivery leads to cell death (13) . While the introduction of short single-stranded oligodeoxynucleotide (ssODN) HDR templates did not cause significant loss of viability in T cells, larger linear dsDNA templates led to extensive toxicity (14, 15) . We found that long (>1kb) linear dsDNA templates were less toxic when they were co-electroporated with a CRISPR-Cas9 ribonucleoprotein (Cas9 RNP) ( fig. S1 ). This suggested that co-delivery of an appropriate mixture of Cas9 RNPs and long dsDNA would enable HDR and preserve cell viability.
We systematically optimized non-viral genome targeting in primary human T cells. The protocol was adjusted for efficiency of target integration, cell viability, and the total number of integration-positive cells (Fig. 1A and fig. S2 ). Cas9 RNPs were electroporated along with a dsDNA HDR template designed to introduce an N-terminal GFP-fusion to the housekeeping gene RAB11A (Fig. 1B) . High-throughput flow cytometry performed 3-5 days after electroporation was used to monitor integration and cell viability. First, we identified stimulation and cytokine treatments both before and after electroporation that markedly increased rates of gene targeting (Fig. 1C and fig. S3 and S4). These conditions allowed efficient targeting in fresh or frozen primary T cells isolated from a variety of sources ( fig. S5 ). Varying ratios of Cas9 RNP and HDR template concentrations were tested at different amounts in these well-stimulated T cells, (Fig. 1D and fig. S6 ), and appropriate concentrations were identified that enabled efficient gene targeting. Finally, we tested electroporation conditions to maximize gene targeting while preserving high levels of cell viability (Fig. 1E and fig. S7 ). Non-viral gene targeting could achieve introduction of a GFP fusion to the endogenous RAB11A housekeeping gene in over 50% of cells in both primary human CD4+ and CD8+ T cells (Fig. 1F) .
Rapid and combinatorial gene targeting applications
The simplicity and speed of non-viral gene targeting allowed us to apply it across genomic sites and human blood donors ( Fig. 2 and fig. S2 ). Constructs encoding GFP-fusions with homologous flanking sequences were efficiently and reproducibly targeted to a variety of sites throughout the genome ( Fig. 2A and fig. S8 ). These targeted GFP fusions labeled a variety of sub-cellular structures (17) . Confocal microscopy confirmed the specificity of the fusion proteins produced by targeting diverse genes, and also demonstrated that targeting endogenous genes with GFP enabled imaging of protein localization in living human T cells (Fig. 2B) . In cells from a cohort of a dozen healthy human donors, targeting GFP integrations into diverse genes proved highly reproducible in primary human T cells ( fig. S8 and S9 ). The specificity of the targeted integrations and the cell-type specific expression pattern of the tagged genes was confirmed further by tagging the endogenously-encoded CD4 surface receptor with GFP. We observed a linear relationship between CD4 and GFP expression specifically in tagged CD4+ T cells but not in CD8+ T cells (Fig. 2C) . Taken together, these findings establish that non-viral genome targeting can be used to modify endogenous genes by inserting large DNA sequences into targeted sites in the genome.
Fusion tags not only permitted imaging of endogenous proteins, but also could be used for biochemical targeting of specific proteins. For example, ChIP-Seq, and more recently CUT & RUN (18) , are widely used to map transcription factor binding sites; however these assays are often limited by availability of effective and specific antibodies. As a proof-of-principle we used anti-GFP antibodies to perform CUT & RUN in primary T cells where the endogenous gene encoding BATF, a critical TF, had been targeted to generate a GFP-fusion. Binding sites identified with anti-GFP CUT & RUN closely matched the sites identified with anti-BATF antibody (Fig. 2D and fig. S10 ).
Targeting two alleles of the same gene with two distinct fluorophores would provide a way to quantify and enrich cells with bi-allelic gene modifications. We introduced two distinct fluorescent proteins targeting the same site at the RAB11A gene (Fig. 3A and fig. S11 ) and showed that >5% of cells had successful bi-allelic integrations. Importantly, the number of cells that express both fluorescent proteins underestimates the percentage of cells with bi-allelic integrations because some cells will have received either GFP or mCherry on both alleles. We constructed a model to account for homozygous integrations of the same fluorescent protein (Fig. 3B, fig. S11 and supplementary text). This model estimates that there were bi-allelic integrations in the RAB11A gene in up to ~10% of cells. This suggests that cells with one RAB11A integration are more likely to have also undergone a second targeted integration, and this effect was observed across three genomic loci ( fig. S11 ). Co-delivery of three fluorescenttags targeting the RAB11A locus demonstrated very low rates of cells that express all three fluorophores, consistent with low rates of off-target integrations in these experiments (fig. S11G). In summary, using multiple non-viral constructs to targeting the same locus allows identification of bi-allelic genome editing in human T cells.
Multiplex editing of combinatorial sets of genomic sites would offer expanded research and therapeutic applications. We tested whether multiple non-viral HDR templates could be codelivered with multiple RNPs to generate primary cells with more than one modified locus. We found not only that multiplexed gene targeting was possible (Fig. 3C) , but that cells with two modifications were enriched by gating on the cells that had one modification ( Fig. 3D and fig.  S12 ) (19) . We were also able to achieve triple gene targeting and could significantly enrich for cells that had a third modification by gating on the cells with two targeted insertions ( Fig. 3E  and fig. S12 ). Overall, non-viral gene targeting can be used to enable complex genetic modifications of primary T cells that could be used for a variety of research and therapeutic applications.
D10A nickase and ssDNA HDR templates reduce off-target integrations
One of the major concerns using HDR templates, especially for therapeutic applications, is the potential for off-target integrations. This has been observed even when integrase-deficient AAVs were used as donor templates (20) . We similarly found evidence of functional off-target integrations using a linear dsDNA template for non-viral gene targeting. Double-stranded DNA templates can integrate in an HDR-independent manner at sites of naturally occurring dsDNA breaks (21) , as well as at the specific dsDNA breaks induced by targeted nucleases such as Cas9 -an effect called Homology-Independent Targeted Integration (22, 23) . We looked for unintended non-homologous integrations using an N-terminal GFP-RAB11A fusion construct which contained the endogenous RAB11A promoter sequence within its 5' homology arm; this construct can drive GFP expression at off-target integration sites ( Fig. 4A and fig. S13 ). We found that functional off-target integrations were present in cells from different biological donors (Fig. 4B) , and were seen in experiments with different target sequences and HDR templates (fig. S13 and S14). Off-target integrations must be minimized in cells destined for therapeutic use to ensure that integrated sequences remain under proper endogenous regulation and that off-target sites are not disrupted.
To reduce off-target integrations caused by off-target Cas9 cutting, we performed nonviral gene targeting using the D10A Cas9 nickase variant. This variant requires that two gRNAs bind and cleave in close proximity to produce a double strand break, thus reducing the number of off-target dsDNA breaks (24) (25) (26) . We tested a series of gRNA combinations at the RAB11A locus for GFP integration, and found a set of "PAM-Out" guides that showed efficient introduction of GFP when using the D10A nickase ( fig. S15 ). As expected, use of D10A with a single off-target guide showed markedly reduced functional off-target integrations when compared to Cas9, equivalent to the level seen when nuclease-incompetent dCas9 was used (Fig.  4C) .
Even using the D10A nickase, dsDNA HDR templates still gave rise to rare but observable off-target integrations (comparable to the rate observed with no Cas9 nuclease), perhaps at naturally occurring dsDNA breaks ( Fig. 4A and C) . We reasoned that the remaining off-target integrations could be eliminated by replacing the dsDNA HDR templates with long ssDNA HDR templates, which cannot integrate non-specifically at double strand breaks (27, 28) . To test this hypothesis, we generated ssDNA HDR templates with two methods we recently developed that produce the large amounts of long ssDNA required for electroporation (fig. S16) (28) ssDNA HDR templates reduced functional off-target integrations approximately 100-fold, while maintaining efficient on-target integration ( Fig. 4D and fig. S16 ). We were able to use D10A Cas9 nickase with ssDNA templates. In these experiments, although on-target integration rates were reduced, non-specific integrations were reduced to background levels seen without template ( Fig. 4E and F) . For sites where potential off-target activity is a concern, D10A Cas9 nickase and ssDNA HDR templates can be employed to reduce the rates of integration arising from off-target induced double strand breaks and naturally occurring breaks respectively, which may make this an attractive method for therapeutic modification of patient T cells.
Therapeutic mutation correction by non-viral gene targeting
We sought to apply non-viral gene targeting to correct the mutations that cause monogenic immune dysregulation in T cells from patients. We identified a family with monogenic primary immune dysregulation with autoimmune disease caused by recessive loss-offunction mutations in the gene encoding the IL-2 alpha receptor (IL2RA), also known as CD25 (29) (30) (31) . IL2RA is essential for Tregs and immune homeostasis (32, 33) , and the children in the family who are compound heterozygotes with two loss-of-function mutations have pleiotropic autoimmune manifestations ( Whole exome sequencing revealed that the IL2RA deficient children harbored compound heterozygous mutations in IL2RA (Fig. 5A and fig. S18 ). One mutation at c.530A>G creates a premature stop codon. Improvements in cell culture and electroporation methodologies made it possible to efficiently correct the mutation using ~120 bp chemically synthesized ssDNA HDR templates ( fig. S19 ). Rates were even higher using a longer dsDNA template (Fig. 5B and fig.  S19 and S20). The corrected patient-derived T cells expressed IL2RA on their surface. Although correction was successful in all three siblings, lower rates of IL2RA expression were seen in compound het 3, which could be due to altered cell-state associated with the patient's disease or the fact she was on the only sibling treated with immunosuppression (Table 1 and fig. S21 ). The second mutation, c.800delA, causes a frameshift in the reading frame of the final IL2RA exon resulting in misreading of the portion of the gene encoded in the final exon as well as run-on translation past the normal stop codon. This frameshift could be ameliorated even without an HDR template ( fig. S20 ). At this site, genomic cutting caused by a Cas9 RNP alone was sufficient to cause productive cell surface expression of IL2RA, likely by restoring the correct frame with insertion/deletion mutations ( fig. S20 ). Taken together, these data show how distinct mutations can be corrected in patient T cells with HDR template-dependent and non-HDR template-dependent repair mechanisms.
One potential therapeutic strategy for patients from this family with monogenic Treg defects would be ex vivo T cell gene correction followed by transfusion of autologous corrected Tregs. Treg cells produced by targeted correction could limit some of the potential risks of hematopoietic stem cell transplantation. We tested whether correcting one of the IL2RA mutations led to productive signaling and whether or not correction occurred in a meaningful fraction of FOXP3+ Tregs. Following correction of the c.530A>G mutation, cells were able to functionally signal through IL2RA, the high-affinity IL-2 receptor. In response to IL-2 treatment, the modified cells demonstrated increased STAT5 phosphorylation, a hallmark of productive signaling (Fig. 5C and fig. S19 and S20 ). In addition, flow cytometry confirmed that a fraction of IL2RA corrected cells expressed FOXP3, a critical transcriptional factor in Tregs (Fig. 5D and  fig. S19 and S20 ).
The endogenous gene encoding IL2RA is under tight control by multiple cis-regulatory elements that constitute a super-enhancer (34, 35). Therefore, therapeutic correction of IL2RA is likely to depend on specific repair of the gene in its endogenous genomic locus. Given that GFP insertions with Cas9 and dsDNA showed that there is a potential for non-specific integrations of dsDNA, we used D10A Cas9 nickase and a long ssDNA template to specifically repair the c.530A>G patient mutation. Using these reagents we were able to specifically and selectively correct the mutant gene in ~20% of the T cells from the patient (Fig. 5E) .
Non-viral gene targeting enables efficient insertion of defined sequences throughout the genome of primary human T cells. These insertions can range from the introduction or correction of single base pair mutations, to integration of large functional sequences and tags at endogenous loci, and multiplexed integrations throughout the genome are possible. For therapeutic applications of engineered T cells, off-target integrations can be significantly reduced by using D10A Cas9 nickase and a ssDNA HDR template. Our findings will enable the accelerated development of engineered T cell therapies and the treatment of genetic disease.
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peer RNPs and a RAB11A-GFP dsDNA HDR template were electroporated into primary human T cells. dsDNA template alone, or with an RNP containing a scrambled gRNA matching no sequence in the human genome yielded small but detectable amounts of GFP expression, which was noticeably increased when a dsDNA template is electroporated with a gRNA targeting a site different from the targeted RAB11A-GFP integration site (the "off-target RNP" targets CXCR4 Exon 1). (B) Off-target integrations were consistently present in cells from different donors when the RAB11A-GFP dsDNA HDR template was electroporated with the off-target RNP, and fewer off-target integrations occurred when the dsDNA HDR template alone was electroporated. (C) Cas9 nuclease variants D10A (nickase) and inactive dCas9 significantly decreased off-target integrations when a single offtarget CXCR4 gRNA was used, but D10A nickase (with an "On-target" pair of gRNAs in a PAM-out orientation) led to efficient on-target integration of the RAB11A dsDNA HDR template. (D) Electroporation of a ssDNA HDR template reduced the off-target integrations to the limit of detection (comparable to levels with no template electroporated) both with no nuclease added and at induced off-target dsDNA breaks (Off-target gRNA + Cas9). (E to F) For integration of GFP fusion at the RAB11A site, use of a D10A nickase with a ssDNA HDR template reduced the on-target HDR (GFP integration with on-target gRNA) compared to Cas9 with a dsDNA template, but strongly reduced off-target integrations to undetectable levels. All fluorescent readouts were performed 4 days post-electroporation. Displayed data is representative of at least two different donors (A and E) or the averages of two different donors (C, D, and F) with standard deviation shown.
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